Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

Affiliations

• ¹ Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg. Niels.Weinhold@med.uni-heidelberg.de.
• ² Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg.
• ³ Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds.
• ⁴ Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg.
• ⁵ Division of Genetics and Epidemiology, The Institute of Cancer Research, London.
• ⁶ Medical Clinic, Charité University Medicine Berlin, Berlin.
• ⁷ Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg.
• ⁸ Perlmutter Cancer Center, NYU Langone Health, New York.
• ⁹ Institute of Human Genetics, University of Heidelberg, Heidelberg.
• ¹⁰ Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz.
• ¹¹ Leeds Institute of Cancer and Pathology, University of Leeds, Leeds.
• ¹² Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne.
• ¹³ Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg.
• ¹⁴ Department of Haematology, University of Newcastle, Newcastle Upon Tyne.
• ¹⁵ Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; Department of Haematology, The Royal Marsden Hospital, London. martin.kaiser@icr.ac.uk.